



ASX Announcement

30 September 2025

Cambium Bio Signs Manufacturing MOU with Locus Cell for Global Commercial Production of Elate Ocular® Active Biologic Ingredient

Sydney, Australia; 30 September 2025: Cambium Bio Limited (ASX:CMB) ("Cambium Bio", "Cambium" or "Company"), a clinical-stage regenerative medicine company, is pleased to announce the execution of a Memorandum of Understanding (MOU) with Taiwan-based Locus Cell Co., Ltd. (TWSE: 6891) for the contract manufacturing of the Active Biologic Ingredient (ABI) for Elate Ocular®, the Company's lead Phase 3 dry eye disease therapy.

Key Highlights

- **Strategic Manufacturing Partnership:** Locus Cell to serve as contract manufacturing organisation (CMO) for commercial-scale production of Elate Ocular® ABI
- **Global Territory (excluding Europe and Middle East):** Manufacturing rights cover worldwide markets except Europe and Middle East, complementing recent Benta SAS licensing MoU
- **FDA GMP-Compliant Facility:** Locus Cell's new Zhubei smart GMP facility designed to meet FDA inspection and certification requirements
- **Related Party Transaction:** MOU includes Zheng Yang Biomedical Technology Co., Ltd. (ZYBT), Cambium's major shareholder (28.1% interest), as technology transfer partner
- **Non-Exclusive Arrangement:** Cambium retains flexibility to engage additional CDMOs as needed for global supply chain optimisation

Partnership Details

Under the terms of the MOU:

Manufacturing Scope

- Locus Cell will manufacture the Active Biologic Ingredient (ABI), the drug substance component of Elate Ocular® based on pooled fibrinogen-depleted human platelet lysates
- Manufacturing rights are limited to ABI production; final drug product formulation remains with Cambium
- All supply will be exclusively to Cambium or its designees under future definitive Supply and Quality Agreements

Technology Transfer

- ZYBT, as the Cambium's technology partner, will provide manufacturing protocols and conduct technical transfer to Locus Cell
- Cambium will assist with FDA inspection preparation and GMP certification processes for the Zhubei facility

Territory and Commercial Terms

- Manufacturing activities cover global markets excluding Europe and the Middle East
- Non-exclusive arrangement allows Cambium to maintain supply chain flexibility
- Two-year initial term with mutual extension options
- All regulatory filings, CMC dossiers, and related data remain Cambium's confidential information

Related Party Disclosure

ZYBT is a substantial shareholder of Cambium Bio, holding approximately 28.1% of the Company's issued capital. ZYBT's participation in this MOU as the technology transfer partner constitutes a related party transaction under ASX Listing Rules. The Board (with interested directors abstaining) has reviewed and approved this arrangement, determining it to be on arm's length terms and in the best interests of all shareholders. No shareholder approval is required as the MOU is non-binding and does not involve any payment or consideration between the related parties.

Strategic Rationale

Karolis Rosickas, Chief Executive Officer of Cambium Bio, commented:

"This manufacturing partnership with Locus Cell represents a critical milestone in our commercialisation strategy for Elate Ocular®. Their state-of-the-art Zhubei facility, with its digital-enabled GMP capabilities and FDA-readiness, positions us to meet global demand as we advance through Phase 3 trials. Combined with our recent

European and Middle Eastern licensing agreement with Benta SAS, we now have a comprehensive global manufacturing and distribution framework in place."

Jiunn-Rong Chiou, Chairman of Locus Cell, stated:

"We are honoured to be selected as Cambium's manufacturing partner for this innovative ophthalmology therapeutic. Our investment in FDA-compliant smart manufacturing infrastructure demonstrates our commitment to serving international pharmaceutical partners. This partnership validates our 'rooted in Taiwan, serving global clients' vision."

About Locus Cell Co., Ltd.

Locus Cell (TWSE: 6891) is a leading regenerative medicine contract development and manufacturing organisation (CDMO) based in Taiwan. The company's new Zhubei smart GMP facility incorporates advanced digital systems for electronic batch records, traceability, environmental monitoring, and data integrity to meet international regulatory standards, including FDA requirements.

Forward-Looking Statements

This announcement contains forward-looking statements regarding manufacturing capabilities, regulatory approvals, clinical development timelines, and commercialisation plans. These statements are based on current expectations and are subject to risks and uncertainties that could cause actual results to differ materially. Factors that could affect outcomes include regulatory delays, clinical trial results, manufacturing scale-up challenges, and market conditions.

Important Notice

This MOU is non-binding (except for confidentiality provisions) and does not create any obligation to execute definitive agreements. The execution of binding Supply and Quality Agreements remains subject to further negotiations, satisfactory completion of facility inspections, and Board approvals.

- ENDS -

About Cambium Bio Limited

Cambium Bio Limited (ASX:CMB) is a Sydney-based clinical-stage regenerative medicine company focusing on the development of innovative biologics for ophthalmology and tissue repair applications. The Company's proprietary technology, based on human platelet lysate, is being leveraged to create a pipeline of novel therapeutics, with a primary focus on ophthalmology. Cambium Bio's lead product candidate, Elate Ocular®, is being developed to address significant unmet medical needs in the treatment of dry eye disease. In addition, the Company's stem cell platform, Progenza™, is being applied to the development of therapies for knee osteoarthritis and other tissue repair indications. Cambium Bio is committed to advancing its pipeline through clinical development and commercialisation, with the goal of providing transformative treatments to improve patient outcomes. For more information about the Company and its programs, please visit www.cambium.bio

Authorisation & Additional Information

This announcement was authorised by the Board of Directors of Cambium Bio Limited.

For further information, please contact:
Acclime Australia – Company Secretary
Email: info@cambium.bio

Cambium Bio Limited
Unit 2.06/31 Lexington Drive, Bella Vista, NSW 2153 Australia
ABN 13 127 035 358
Phone: 1300 995 098
www.cambium.bio